Published in JAMA Oncology · View the paper (DOI)
Dropping the cancer label from grade group (GG)1 prostate disease redefines it as a precancerous lesion, leading to a net reduction in estimated prostate cancer deaths. This relabeling strategy may have minimal impact on screening rates.
Coverage from 2 institutions